Method for preparing substance with anti-tumour activity accompanying hepatocellular carcinoma
SUBSTANCE: invention represents a method for preparing a substance with anti-tumour activity in hepatocellular carcinoma consisting in the fact that individual's enteric mucosa is homogenised with water in ratio 1:3-5 at +3-+5°C; the homogenate is centrifuged; the supernatant is heated for 7-10 min at temperature 20° to 38°C increased to 100°C and heated to 15-20 min at this temperature, centrifuged again; the cooled supernatant cooled to +4-+6°C is added with ethanol cooled (-15)-(-20)°C to the concentration of 65-70%; 15-17 h later it is centrifuged again; the alcohol is removed from the supernatant; the prepared end product is frozen and stored at (-65)-(-70)°C until used.
EFFECT: extended range of products possessing the anti-tumour activity.
1 tbl, 1 ex
The present invention relates to methods of producing biologically active compounds that can be used in medicine to inhibit the growth of malignant tumors.
A method of obtaining antitumor agents from the mucosa of the small intestine of the pig, including homogenization, processing ethyl alcohol, heating to 70°C, ultrafiltration and lyophilization [United States Patent 6,015,878, Jan. 18, 2000. Trifonov Monday Centuries, Roussev Je. K., Boshev N. A. Antitumor aqents isolated from intestinal mucosa, a method for their isolation and their application]. These agents have anti-tumor activity against lymphoma and myeloma mice, carcinoma of the pharynx and epithelioid carcinoma of the bladder, the embryonic rhabdomyosarcoma.
The objective of the invention is a method for antitumor substances (PS), which has activity against hepatocellular cancer.
The problem is solved by a method of obtaining PV, namely, that the mucous membrane of the small intestine of man homogenized with water in a ratio of 1:3-5 +3-+5°C, the homogenate was centrifuged, the supernatant heat for 7-10 minutes at a temperature of from 20 to 38°C, adjusted to 100°C. and heated for 15-20 minutes at this temperature, centrifuged again, cooled to +4 to+6°C. the supernatant add cooled to -15)-(-20)°With ethanol to a concentration of 65-70%, stand 15-17 h at (-15)-(-20)°C, t see you a again is centrifuged, from the supernatant removed the alcohol obtained target product is frozen and stored at (-65)-(-70°C until use.
Distinctive features of the proposed method are used as the feedstock of the mucous membrane of the small intestine of man, centrifugation of the homogenate in distilled water, warming the supernatant at a temperature of from 20 to 38°C, bringing the temperature up to 100°C and holding for 15-20 min at this temperature, centrifugation after warming up, processing ethanol to a concentration of 65-70%, keeping with ethanol 15-17 h at (-15)-(-20)°C, centrifugation.
Tests of the inventive PV on cytotoxic (cytotoxic and antitumor activity were carried out on cultures of tumor cells in vitro and in rats with transplantable tumors (in vivo).
The following examples illustrate the method of obtaining the RO and the determination of its biological activity.
1. An example of obtaining the RO.
During resection of the small intestine of man produce fence resected part of the small intestine length of 5 cm, which lacks any education. Immediately after collection to separate the mucous membrane. Its weight is 2.5, the Mucous membrane is shredded, add 7.5 ml of distilled water, homogenized with +3-+5°C, the homogenate was centrifuged to precipitate nuclei (1000 rpm, 10 min). Received posthegemony native supernatant is heated on a water bath for 7-10 minutes at a temperature of from 20 to 38°C, adjusted to 100°C and incubated for 15-20 min at 100°C. the Formed precipitate thermolabile material removed by centrifugation (5000 rpm, 15 min). To the supernatant, cooled to +4-+6°C, add 16,1 ml of 96% ethanol, cooled to -15)-(-20)°C and left at this temperature for 15-17 h, centrifuged in the same mode, which is indicated above. The alcohol from the supernatant removed with a rotary evaporator. The obtained extract (4 ml) is the concentration of protein 14,0-17,0 mg/ml in optical absorption at D280. Extract (PV) frozen and stored at 65-70°C until use.
2. Determination of activity declared by the RO on the culture of tumor cells hepatoma-27, are in the growth stage.
To perform this work hepatoma-27 was transferred into the culture of subcutaneous tumors by trypsinization. This scored a rat with subcutaneous hepatoma, sterile removed the tumor, chose the site free from necrosis. Separated him, were placed in a chilled solution of trypsin : versene (1:1) and 24 h were kept at +4°C. the next day poured trypsin : versen, washed several times with Hanks solution, filled in standard culture medium with 10% fetal serum and 100 µg/ml gentamicin and were sown on bottles Carell. After 24 h about the-Odile change the environment to remove not adherent cells. Cells were cultured in the medium of DMEM+RPMI (1:1) supplemented with 5% fetal calf serum (Flow).
Cells were planted in 96-well plates (Costar) in 100 μl of culture medium (DMEM+RPMI (1:1)). The number of cells introduced into the hole, depended on the duration of the experiment: 1 day - 4 thousand per well, 3 days - 2 thousand per well, 6 days - 1 thousand per well. Preincubation (culturing cells without drug) was carried out for 24 h at 37°C in an atmosphere of 5% CO2. Otany PV contributed to the wells at concentrations of 0.25; 0.5; 1.0 and 2.0 mg/ml of culture medium. Incubation was carried out at 37°C for 1, 3 and 6 days.
MTT [3-(4,5-dimethanol-2)2.5 diphenyltetrazolium bromide] (Sigma), dissolved in water, was added in 20 μl (original solution of 5 mg/ml) in each well for 3 hours under the same conditions. Then the medium was collected and for lysis of cells used dimethyl sulfoxide (60 μl/well). For homogeneous distribution of the dye lysate was thoroughly mixed on a shaker (300 rpm) for 3 minutes. Quantitative determination of formazan conducted on the device Multiskan (filter 540). Cell viability was assessed by the ratio of the optical density of the solutions in the wells with the control cells and in the wells with cells treated with RO.
The inhibition of proliferation of cells in culture hepatoma-27 was calculated by the formula:
FE - ing the repression of proliferation;
In the level of proliferation in the experience;
PC - level proliferation in control.
The table presents data on the impact of PV on the growth of culture cells hepatoma-27 at various concentrations of protein PV in 1 ml of culture medium.
The table shows that on the 1 day of incubation PV presents all concentrations had no inhibitory effect on the proliferation of tumor cells. On the 3rd day of incubation PV in all concentrations exerted a cytotoxic effect on tumor cells. The greatest inhibitory effect possessed by the RO at a concentration of 2 mg per 1 ml of medium. On the 6th day of incubation compared with 3 days cytotoxic effect of all PV was increased, the inhibition of cell proliferation was most pronounced in extracts with protein concentration, equal to 1 and 2 mg/ ml of culture medium.
Thus, the claimed PV is characterized by a high level of inhibition of cell proliferation in cell cultures of hepatoma-27, reaching 73% (on the 3rd day of incubation) and 92% (6 days).
3. The determination of the activity of the claimed ROS in vivo.
The study was carried out on outbred rats male weighing 100-150 g intertwined with intrahepatic hepatoma-27. For this purpose, 10 days after inoculation of tumor of the liver produced re-laparotomy, measured the size of the tumor (2nd largest size), after which the wound is arena the abdominal wall is sutured. Animals were divided into 2 groups. In group 1 was carried out by intraperitoneal injection of PV at the rate of 100 mg of protein per kg of body weight in a volume of 1 ml. Introduction were made every other day for 14 days (total of 7 injections). Animals of group 2 was the control, the PV they were introduced. 6 days after the last injection, the rats of group 1 (20 days after the start of treatment and 30 days after inoculation of tumor) animals of both groups were scored and again measured the tumor.
The rate of inhibition of tumor growth (TRO) was calculated by the formula:
P op. counter - tumor size in control,
P op. experience - the size of the tumor in the experience.
The following has been discovered. 10 days after inoculation of tumor (at start of treatment rats group 1) significant differences in the size of liver tumors in 1 and 2 groups was not: the area of the tumor was, respectively, 27,0±6,7 and 24.7±7.5 mm2P>0,05. 30 days after inoculation of tumor size in rats group 1 increased false, 55.3±18,8 mm2P>0,05, whereas the animals of the 2nd group, the tumor size was significantly increased to 167,7±46.4 mm2, P<0,05. Differences between groups 30 days after inoculation of tumor were reliable, which allows to calculate the indicator TRO. He was 67%.
Thus, the use of declared PV can effectively inhibit the growth of g is patami 27, namely, to stop the proliferation of cancer cells (in vitro) and to contribute to the inhibition of tumor growth in rats (in vivo).
The proposed method allows to extend the range of substances with antitumor activity.
A method of obtaining a substance with antitumor activity in hepatocellular liver cancer, namely, that the mucous membrane of the small intestine of man homogenized with water in a ratio of 1:3-5 +3-+5°C, the homogenate was centrifuged, the supernatant heat for 7-10 minutes at a temperature of from 20 to 38°C, adjusted to 100°C. and heated for 15-20 minutes at this temperature, centrifuged again, cooled to +4 to+6°C. the supernatant add cooled to -15)-(-20)°With ethanol to a concentration of 65-70%through 15-17 h again centrifuged, the supernatant removed the alcohol obtained target product is frozen and stored at (-65)-(-70°C until use.
SUBSTANCE: invention refers to medicine, namely to oncology and immunology, and can be used in treating an individual with a stable pathogenic infection or a tumour. That is ensured by administering a therapeutically effective amount of a programmed death (PD-1) peptide antagonist and a therapeutically effective amount of a pathogen or tumour antigen molecule (vaccine).
EFFECT: invention provides the synergetic action of the antigen and PD-1 antagonist (anti-PD-L1 antibody) combination by intensifying the T-cell immune response to the pathogen or tumour.
14 cl, 29 dwg, 5 tbl, 25 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to MUC1 cytoplasmic domain peptides, and can be used in the anticancer therapy. A method for inhibiting MUC1-positive cancer cell in an individual involves administering into an individual the MUC1-peptide of the length of at least 6 sequential MUC1 residues and no more than 20 sequential MUC1residues and containing the sequence CQCRRK, wherein the amino terminal cysteine from CQCRRK is closed at its NH2 terminal by at least one amino acid residue, which shall not conform with the native transmembrane sequence MUC-1. Alternatively, there can be used MUC-1 peptide of the length of at least sequential MUC1 residues and no more than 20 sequential MUC1 residues, which contains the sequence CQCRRK with all amino acid residues of the above peptide being D-amino acids.
EFFECT: invention enables inhibiting MUC1oligomerisation effectively and inducing the tumour cell apoptosis and the tumour tissue necrosis in vivo.
80 cl, 16 dwg, 1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biochemistry, in particular to single variable domain, aimed against IL-6R, to polypeptide and construction, directed against IL-6R, containing said single variable domain, as well as to methods of obtaining them. Disclosed are nucleic acids, coding said single variable domain, polypeptide and construction, as well as genetic constructions, containing said nucleic acids. Described are host cells and host organisms, containing said nucleic acids. Invention also deals with composition for blocking interaction of IL-6/IL-6R, containing effective quantity of described single variable domain, polypeptide, construction, nucleic acid or genetic construction. Also disclosed is method of prevention and/or treatment of at least one of diseases or disorders, associated with IL-6, IL-6R, complex IL-6/IL-6R and/or signal pathways, in which IL-6, IL-6R or complex IL-6/IL-6R is involved and/or biological functions and reactions, win which IL-6, IL-6R or complex IL-6/IL-6R takes part with application of described single variable domain, polypeptide, construction or composition.
EFFECT: invention makes it possible to block interaction of IL-6/IL-6R effectively with increased affinity and biological activity.
25 cl, 70 dwg, 56 tbl, 61 ex
SUBSTANCE: invention refers to biotechnology, in particular to tumour-specific promoters, and can be used in the anti-cancer therapy. There are constructed the broad-spectrum tumour-specific promoters providing the therapeutic gene expression inside a cancer cell. The invention also involves expression cassettes, expression vectors, pharmaceutical compositions, methods of treating cancer and using the expression cassettes and vectors.
EFFECT: promoters of the present invention provide a high expression level of the operatively linked therapeutic gene in the cancer cells of different origin, wherein the normal cell expression is absent or low.
29 cl, 19 dwg, 4 tbl, 20 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to specific compounds or their therapeutically acceptable salts presented in the patent claim and representing sulphonyl benzamide derivatives. Besides, the invention refers to a pharmaceutical composition and a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, stomach cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, T-cell or B-cell lymphoid process, melanoma, myelogenic leukaemia, myeloma, oral cancer, ovarian cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, spleen cancer with the above composition containing an excipient and a therapeutically effective amount of the sulphonyl benzamide derivative or its therapeutically acceptable salt.
EFFECT: preparing the new pharmaceutical composition.
5 cl, 45 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel compounds of formula Ia, their stereoisomers or pharmaceutically acceptable salts, inhibiting JAK kinase activity. Compounds can be applied in treatment of inflammatory diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis, in treatment of autoimmune diseases, such as lupus, multiple sclerosis, neurodegenerative diseases, such as Alzheimer's disease, etc. In formula Ia R1 represents H; R2 represents -OR4, -NR3R4- or -NR3S(O)2R4; R3 represents H or C1-C6alkyl, where said alkyl is optionally substituted with ORa; R4 represents H, C1-C6alkyl, -(C0-C5alkyl)(C3-C6cycloalkyl), -(C0-C5alkyl)(C4-C5heteroaryl), where heteroaryl contains 1-2 nitrogen atoms as heteroatoms, or -(C0-C5alkyl)(C6aryl), where said alkyl is optionally substituted with group R8 and said aryl, cycloalkyl and heteroaryl are optionally substituted with group R9; or R3 and R4, taken together with nitrogen atom, which they are bound to, form C3heterocyclyl, containing 1 nitrogen atom as heteroatom, optionally substituted with group R13; Z represents -NR5R6; R5 represents H; R6 represents H, C1-C10alkyl, -(C0-C5alkyl)(C4-C5heterocyclyl), where heterocyclyl contains oxygen atom as heteroatom, -(C0-C5alkyl)(C3-C8cycloalkyl), -(C0-C5alkyl)(C3-C5heteroaryl), where heteroaryl contains 1 nitrogen atom or 1 oxygen atom or contains 2 atoms, selected fromoxygen, nitrogen and sulphur, as heteroatoms, -(C0-C5alkyl)(C6aryl), where said alkyl is optionally substituted with group R10, and said aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted with group R11; R7 represents H; R8 and R10 each independently represents halogen or ORa; R9 independently represents -CN, -CF3, halogen, -C(O)ORa, -C(O)NRaRb, -(C0-C5alkyl)NRaRb, -(C0-C5alkyl)ORa, -(C0-C5alkyl)SRa, -O[C(Ra)2]1-3O-, C1-C3alkyl, optionally substituted with F, -(C0-C5alkyl)(C3-C6cycloalkyl), optionally substituted with group oxo or F, -(C0-C5alkyl)C3-C6heterocyclyl, where heterocyclyl contains 1-2 heteroatoms, selected from atoms of oxygen and nitrogen, and where heterocyclyl is optionally substituted with halogen or C1-C3alkyl, -(C0-C5alkyl)C6aryl, optionally substituted with halogen, or -(C0-C5alkyl)C4-C5heteroaryl, where heteroaryl contains 1 nitrogen atom or 1 oxygen atom or contains 2 atoms, selected from atom of oxygen, nitrogen and sulphur as heteroatoms, and where heteroaryl is optionally substituted with or C1-C3alkyl; R10 independently represents halogen or ORa. Other values of radicals are given in the invention formula.
EFFECT: obtaining pharmaceutically acceptable salts, inhibiting JAK kinase activity.
15 cl, 4 tbl, 452 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula I , II or IV , wherein the radical values W, V, Ra, Rb, X, L, Rt, A are presented in the patent claim.
EFFECT: declared compounds identify and bind the CA-IX protein; they can contain a radioactive element for radionuclide imaging or therapeutic application.
27 cl, 1 tbl, 5 dwg, 25 ex
SUBSTANCE: treating locally advanced oropharyngeal cancer is ensured by a radiation therapy in the mode of dynamic dose fractionation. The radiation therapy is started by supplying a fraction dose of 2.4 Gy. After 2 days of treatment gap, the patient is exposed to total fractions at a fraction dose of 3.6Gy for three days. Each session is precede by placing high-structure hydrogel matrix of sodium alginate under a patient's tongue with metronidazole 150mg and bilberry 20-35mg pre-introduced into the matrix, for 4-5 hours twice every 1-2 hours. The two following sessions of the exposure at a fraction dose of 2.4 Gy are preceded by placing the matrix once under the tongue for 4-5 hours. After 2 days of treatment gap, the following 5 sessions of the radiation therapy are performed at a fraction dose of 2.4 Gy to a cumulative dose of 30Gy. Colegel-DNA-Ch high-structure disk is preliminary placed under the tongue for 4-5 hours.
EFFECT: method enables avoiding the compulsory gaps of the radiation therapy by reducing a rate of severe local radiation reactions, and provides the target delivery and accurate dosage of metronidazole administered into the patient's body leading to the partial death of well-oxygenated cells and re-oxygenation of hypoxic tumour cells.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula or its therapeutically acceptable salts, wherein A1 represents furyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, thienyl, triazolyl, piperidinyl, morpholinyl, dihydro-1,3,4-thiadiazol-2-yl, benzothien-2-yl, banzothiazol-2-yl, tetrahydrothien-3-yl, [1,2,4]triazolo[1,5-a]pyrimidin-2-yl or imidazo[2,1-b][1,3]-thiazol-5-yl; wherein A1 is unsubstituted or substituted by one, or two, or three, or four, or five substitutes independently specified in R1, OR1, C(O)OR1, NHR1, N(R1)2, C(N)C(O)R1, C(O)NHR1, NHC(O)R1, NR1C(O)R1, (O), NO2, F, Cl, Br and CF3; R1 represents R2, R3, R4 or R5; R2 represents phenyl; R3 represents pyrazolyl or isoxazolyl; R4 represents piperidinyl; R5 represents C1-C10alkyl or C2-C10alkenyl each of which is not specified or specified by substitutes specified in R7, SR7, N(R7)2, NHC(O)R7, F and Cl; R7 represents R8, R9, R10 or R11; R8 represents phenyl; R9 represents oxadiazolyl; R10 represents morpholinyl, pyrrolidinyl or tetrahydropyranyl; R11 represents C1-C10alkyl; Z1 represents phenylene; Z2 represents piperidine unsubstituted or substituted by OCH3, or piperazine; both Z1A and Z2A are absent; L1 represents C1-C10alkyl or C2-C10alkenyl each of which is unsubstituted or substituted by R37B; R37B represents phenyl; Z3 represents R38 or R40; R38 represents phenyl; R40 represents cyclohexyl or cyclohexenyl; wherein phenylene presented by Z1 is unsubstituted or substituted by the group OR41; R41 represents R42 or R43; R42 represents phenyl, which is uncondensed or condensed with pyrrolyl, imidazolyl or pyrazole; R43 represents pyridinyl, which is uncondensed or condensed with pyrrolyl; wherein each cyclic fragment presented by R2, R3, R4, R8, R9, R10, R38, R40, R42 and R43 is independently unsubstituted or substituted by one or more substitutes independently specified in R57, OR57, C(O)OR57, F, Cl CF3 and Br; R57 represents R58 or R61; R58 represents phenyl; R61 represents C1-C10alkyl; and wherein phenyl presented by the group R58 is unsubstituted or substituted by one or more substitutes independently specified in F and Cl.
EFFECT: invention refers to a pharmaceutical composition containing the above compounds, and to a method of treating diseases involving the expression of anti-apoptotic Bcl-2 proteins.
7 cl, 2 tbl, 48 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmacology and oncology, particularly to a new antitumour agent. Beta-ethyldiphacyl is presented to be used as an agent of an epithelial tumour (carcinoma) inhibition. There is provided to administer Ethyldiphacyl in doses of 15-50 mg/kg both before, and after the tumour grafting; the therapeutic course is up to 2 months after the tumour grafting with administrations following every 6-7 days; or preventive administration is performed 2-24 hours before the tumour grafting.
EFFECT: technical effect consists in prolonging the life of mammals suffering the from the tumour by 30%; the life is not burdened with the disease progression.
4 cl, 1 tbl
SUBSTANCE: invention refers to medicine. A method of treating the patients with the complicated forms of diabetic foot by blood sampling, centrifugation, plasma removal, erythrocyte fraction recovery, introduction of the angiotropic drug alprostadil, exposure to laser light at power 12 mWt for 20 minutes, addition of normal saline 100 ml in erythrocyte fraction 200 ml and reinfusion for 1.5-2 hours; ATP 2 ml is combined with the angiotropic drug alprostadil and introduced into the erythrocyte fraction; the erythrocyte fraction is reinfused every second day, alternated with intravenous drop-by-drop introduction of Vessel-DUE-F 600 LSU and actovegin 5 ml per normal saline 100 ml; the therapeutic course is 10 days.
EFFECT: using the method provides higher effectiveness and reduces the length of treatment of the patients with the complicated forms of diabetic foot syndrome, promotes the longer preservation of the achieved therapeutic effect.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves. The method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves consisting in the fact that the multiseptate gastric content and amniotic placental fluid are sampled from female foetus; the multiseptate gastric tissue is homogenised, combined with the amniotic placental fluid, settled, filtered, centrifuged; a produced liquid fraction is combined with the multiseptate gastric content in the certain environment.
EFFECT: preparation produced by the method described above possesses the improved therapeutic action in the newborn calves suffering dyspepsia.
SUBSTANCE: method involves dietotherapy that is M.I. Pevzner's diet No. 5, therapeutic exercises and oral administration of the preparation Enterosan. Enterosan is dosed one capsule 5 times a day after meals for 2-3 weeks. The administration is combined with general magnetotherapy. That is ensured by exposure to low-frequency traveling pulse magnetic field of frequency 100 Hz and magnetic induction gradually increasing within 10 % to 80 % from the maximum value 3.5 mT. The magnetic field is directed forward - backward - forward. Exposure time is 20-25 minutes. 4-5 procedures are performed every week. The therapeutic course is 8-10 procedures.
EFFECT: method provides intensification of general and hepatic haemodynamics, improvement of bile production and secretion processes, elimination of inflammatory process, normalisation of a gastric and pancreatic secretory function, correction of motor-evacuation and microbiotic intestinal disorders, lower lipid peroxidation activity and stimulation of antioxidant system activity.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to pharmacology and medicine. Fin order to obtain medicine, which has tissue-specific activity, animal organs are subjected to freezing not later than after 2 hours after raw material collection at temperature not lower than 40°C, kept at temperature minus 20-22°C during not less than two months. To milled frozen raw material 5% solution of acetic acid is added, bringing suspension temperature to 60-70°C and extraction of peptides into solution is carried out with constant mixing during not less than 2 hours. Supernatant fluid is siphoned and filtered through tissue, after which purified extract is directed to tangential micro-filtering. Obtained filtrate is directed to solid-phase extraction. Chromatography is carried out and on output from columns fractions of solutions are collected. Fractions, which contain peptide components, are united and directed to vacuum-evaporating plant, after which obtained target product is lyophilised.
EFFECT: method application makes it possible to obtain peptide complex with molecular weight of peptide components included in it from 75 to 5200 Da, which demonstrates pronounced tissue-specific activity.
8 cl, 14 tbl, 14 ex
FIELD: medicine, veterinary science.
SUBSTANCE: invention refers to veterinary science. A method consists in the fact that a flour or an impalpable powder 20.0-50.0 g containing chicken or duck gizzard lining 50.0 g (50 wt %), greater burnet rhizome and root 12.0 g (12.0 wt %), analgin 10.0 g (10.0 wt %), ascorbic acid 8.0 g (8.0 wt %) and glucose 20.0 g (20.0 wt %) is given to a young animal suffering a gastric or intestinal disease associating diarrhoea signs, 5-10 minutes before feeding 1 or 3 times a day.
EFFECT: method exhibits a high therapeutic effect.
FIELD: medicine, veterinary.
SUBSTANCE: invention relates to field of veterinary. Medication contains cuticle of bird gizzard - 60%, iodine - 13%, starch-27%. Medication is simple to manufacture, ecologically pure.
EFFECT: invention is highly efficient for prevention of gastrointestinal diseases in farm animals.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to veterinary science. Specified agent represents mixed lyophilised aqueous extracts of pyloric and fundic gastric, duodenal and pancreatic tissues of pigs and contains a complex of proteolytic enzymes with molecular weight 35000-40000 Da, consisting of pepsin and pepsinogen in the ratio 1:12-1:17 with pH 7.0, others proteolytic enzymes, carboproteinase and other proteases, and also tripsinogen, chemotrypsinogen, trypsin, pantrypsin, chemotrypsin, amylase, lipase, nuclease, elastase, collagenase, dominant amino acids - asparaginic, glutaminic, alanine, glycine, lysine, leucine and valine. The method for making said agent provides aqueous extraction of biological raw materials followed with recovery and further lyophilisation of a supernatant. Method of treating diarrhoea in piglets is characterised by that 25-30 ml of the agent under cl.1 dissolved in 1.5% sodium chloride is orally introduced to piglets with diarrhoea.
EFFECT: development of an effective remedy for treating diarrhoea in piglets
3 cl, 1 tbl, 1 ex
SUBSTANCE: invention relates to medicine, namely to dermatology and cosmetology and can be used for treatment of such skin disease as rosacea. For this purpose Doppler examination of face skin microcirculation is carried out, during which background volume rate of tissue blood flow on affected and unaffected sections of face skin is determined with further comparison of obtained parameters with each other. In case compared parameters have deviation value not less than 10%, base care of face skin is prescribed: use of purifying and moisturising preparations for sensitive skin, microcurrent therapy in lymphodrainage mode for 20 minutes 2-3 tines a week with course of 8-10 sessions, and introduction of Sulodexide 250 LSU after meal with 4-8 week course. In case compared parameters of background volume rate of blood flow have deviation value from 10 to 20% in case of papula-pustular stage of rosacea, course of microcurrent therapy in lymphodrainage mode is carried out 3 times a week with course consisting of 10 sessions, and Sulodexide is introduced with course of 4 weeks. In case compared parameters of background volume rate of blood flow have deviation value from 20% and greater, rosacea stage being hypertrophic, Sulodexide is introduced with course of 8 weeks, and microcurrent therapy in lymphodrainage mode is carried out from 4th week 3 times a week with course consisting of 10 sessions in combination with basic care of face skin.
EFFECT: method allows ensuring stable therapeutic effect including treatment of severe forms of rosacea due to complex influence.
3 cl, 2 ex
SUBSTANCE: invention concerns medicine, particularly abdominal surgery and prevention of anastomosis inefficiency of hollow gastroenteric tract organs of morbid adiposity and metabolic syndrome patients. Method involves Enterosan (E) administration by 2 capsules 3 times per day for two weeks before operation. Then 30-50 ml of E is administered to stomach on the 2nd day after operation in suspension form every 6 hours. Further E is administrated perorally: by 3 capsules 4 times per day on 3rd to 7th days, by 2 capsules 4 times per day on 8th to 12th day, further by 1 capsule 2 times per day for 7-10 days.
EFFECT: reduced inflammatory alterations, accelerated regeneration process in anastomosis area, normalisation of gastroenteric tract function.
5 dwg, 1 ex
SUBSTANCE: group of inventions concerns therapeutic angiogenesis stimulation and generation of trophic and angiogenetic factors, and can be applied in amplification of brain compensation mechanism for functional salvage after central neural system damage or degeneration. The invention claims: a therapeutic medium of angiogenesis and vasculogenesis inducing factors for application in neurological and musculoskeletal therapy, containing angiogenesis and vasculogenesis inducing factors detached from human marrow stem cells in combination with pharmaceutically acceptable therapeutic cell medium; generation amplification method for angiogenesis and vasculogenesis inducing factors released by stem cells involving exposure and joint cultivation of stem cells with a compound for generation improvement of angiogenesis and vasculogenesis inducing factors; angiogenesis and vasculogenesis inducing factors isolated and separated of stem cells for application in therapy; process of obtaining the claimed angiogenesis and vasculogenesis inducing factors, including stages of human mesenchymal stem cell isolation and separation from tissue, differentiation and further cultural cultivation of mesenchymal stem cells for obtaining of neurological and musculoskeletal therapeutic media; mesenchymal stem cells isolated and cultivated in a culture, capable of differentiation and generation of target cell phenotype for tissue recovery under the effect of a required compound.
EFFECT: improved efficiency of cellular therapy.
17 cl, 3 ex, 4 tbl, 9 dwg
FIELD: medicine, gastroenterology, medicinal biochemistry.
SUBSTANCE: invention relates to a method for treatment and choice of a pharmaceutical preparation used in treatment of diseases caused and accompanying with disturbance in metabolism of bile acids and cholesterol. Method involves determination of the quantitative composition of short-chain fatty acids of (C2-C4)-fraction in blood serum and feces. Method involves using preparations containing fatty acids and promoting fro dissolving cholesterol bile stones in case when the content of propionic acid is decreased from 5.6% and increasing the content of butyric acid from 3.5%, and in increasing propionic acid from 19.9% to 21.8% and butyric acid from 18.9% to 20.1% in feces. Method involves administration of preparations effecting on activity of intestine anaerobic microorganisms in case when the content of propionic acid is decreased from 5.7% to 6.5% and the content of butyric acid is increased from 2.9% to 3.4% in blood serum, and when the content of propionic acid is increased from 21.8% and that of butyric acid from 20.1% in feces. Method involves the combination of preparations containing fatty acids and promoting to dissolving cholesterol bile stones and preparations effecting on activity intestine anaerobic microorganisms when the content of propionic acid is decreased from 5.6% and less and the content of butyric acid is increased from 3.5% and above. Proposed method provides possibility for differentiating treatment based on assay of leading ethiopathogenetic mechanisms in development of choledocholithiasis.
EFFECT: improved and enhanced method of treatment.
2 tbl, 3 ex